Drugs

, Volume 33, Supplement 3, pp 186–188 | Cite as

Evaluation of the Efficacy and Safety of Anisoylated Plasminogen Streptokinase Activator Complex in Early Myocardial Infarction

Preliminary Results
  • S. J. Lenhoff
  • A. R. Horak
  • R. C. Fraser
  • R. N. Scott-Millar
  • A. R. Bird
  • P. Jacobs
  • P. J. Commerford
Short Communication Section 2: Efficacy of Anisoylated Plasminogen Streptokinase Activator Complex: Evidence of Vessel Patency: Poster Presentations

Conclusions

In the 15 patients receiving a 20U dose of APSAC administered intravenously, recanalisation was effected in 11 (73%). These results compare favourably with those reported for intravenous tissue plasminogen activator and intracoronary streptokinase. Use of APSAC in this dose was associated with the development of a systemic lytic state in 12 of the 15 patients studied. Apart from a hypotensive reaction in 3 patients, no major adverse reactions attributable to APSAC were observed. Therefore, APSAC in a dose of 20U administered intravenously is safe and effective in the management of patients with early myocardial infarction. Successful coronary thrombolysis was always associated with the development of a systemic lytic state. This did not result in significant haemorrhagic complications in this small number of patients.

Keywords

Streptokinase Angiographic Evidence Anisoylated Plasminogen Streptokinase Activator Complex Anterior Infarction Intracoronary Streptokinase 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Copyright information

© ADIS Press Limited 1987

Authors and Affiliations

  • S. J. Lenhoff
    • 1
  • A. R. Horak
    • 1
  • R. C. Fraser
    • 1
  • R. N. Scott-Millar
    • 1
  • A. R. Bird
    • 1
  • P. Jacobs
    • 1
  • P. J. Commerford
    • 1
  1. 1.Cardiac Clinic, Department of Medicine and Department of HaematologyUniversity of Cape Town and Groote Schuur HospitalCape TownSouth Africa

Personalised recommendations